Preimplantation genetic testing for aneuploidy in uterus transplant patients
Uterus transplantation is an emerging treatment for uterine factor infertility. In vitro fertilization with cryopreservation of embryos prior is required before a patient can be listed for transplant. Whether or not to perform universal preimplantation genetic testing for aneuploidy should be addres...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-04-01
|
| Series: | Therapeutic Advances in Reproductive Health |
| Online Access: | https://doi.org/10.1177/26334941211009848 |
| _version_ | 1830358488143888384 |
|---|---|
| author | Rhea Chattopadhyay Elliott Richards Valerie Libby Rebecca Flyckt |
| author_facet | Rhea Chattopadhyay Elliott Richards Valerie Libby Rebecca Flyckt |
| author_sort | Rhea Chattopadhyay |
| collection | DOAJ |
| description | Uterus transplantation is an emerging treatment for uterine factor infertility. In vitro fertilization with cryopreservation of embryos prior is required before a patient can be listed for transplant. Whether or not to perform universal preimplantation genetic testing for aneuploidy should be addressed by centers considering a uterus transplant program. The advantages and disadvantages of preimplantation genetic testing for aneuploidy in this unique population are presented. The available literature is reviewed to determine the utility of preimplantation genetic testing for aneuploidy in uterus transplantation protocols. Theoretical benefits of preimplantation genetic testing for aneuploidy include decreased time to pregnancy in a population that benefits from minimization of exposure to immunosuppressive agents and decreased chance of spontaneous abortion requiring a dilation and curettage. Drawbacks include increased cost per in vitro fertilization cycle, increased number of required in vitro fertilization cycles to achieve a suitable number of embryos prior to listing for transplant, and a questionable benefit to live birth rate in younger patients. Thoughtful consideration of whether or not to use preimplantation genetic testing for aneuploidy is necessary in uterus transplant trials. Age is likely a primary factor that can be useful in determining which uterus transplant recipients benefit from preimplantation genetic testing for aneuploidy. |
| first_indexed | 2024-12-20T02:43:04Z |
| format | Article |
| id | doaj.art-d7b4d196a333458cba4de2b68b81055f |
| institution | Directory Open Access Journal |
| issn | 2633-4941 |
| language | English |
| last_indexed | 2024-12-20T02:43:04Z |
| publishDate | 2021-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Reproductive Health |
| spelling | doaj.art-d7b4d196a333458cba4de2b68b81055f2022-12-21T19:56:16ZengSAGE PublishingTherapeutic Advances in Reproductive Health2633-49412021-04-011510.1177/26334941211009848Preimplantation genetic testing for aneuploidy in uterus transplant patientsRhea ChattopadhyayElliott RichardsValerie LibbyRebecca FlycktUterus transplantation is an emerging treatment for uterine factor infertility. In vitro fertilization with cryopreservation of embryos prior is required before a patient can be listed for transplant. Whether or not to perform universal preimplantation genetic testing for aneuploidy should be addressed by centers considering a uterus transplant program. The advantages and disadvantages of preimplantation genetic testing for aneuploidy in this unique population are presented. The available literature is reviewed to determine the utility of preimplantation genetic testing for aneuploidy in uterus transplantation protocols. Theoretical benefits of preimplantation genetic testing for aneuploidy include decreased time to pregnancy in a population that benefits from minimization of exposure to immunosuppressive agents and decreased chance of spontaneous abortion requiring a dilation and curettage. Drawbacks include increased cost per in vitro fertilization cycle, increased number of required in vitro fertilization cycles to achieve a suitable number of embryos prior to listing for transplant, and a questionable benefit to live birth rate in younger patients. Thoughtful consideration of whether or not to use preimplantation genetic testing for aneuploidy is necessary in uterus transplant trials. Age is likely a primary factor that can be useful in determining which uterus transplant recipients benefit from preimplantation genetic testing for aneuploidy.https://doi.org/10.1177/26334941211009848 |
| spellingShingle | Rhea Chattopadhyay Elliott Richards Valerie Libby Rebecca Flyckt Preimplantation genetic testing for aneuploidy in uterus transplant patients Therapeutic Advances in Reproductive Health |
| title | Preimplantation genetic testing for aneuploidy in uterus transplant patients |
| title_full | Preimplantation genetic testing for aneuploidy in uterus transplant patients |
| title_fullStr | Preimplantation genetic testing for aneuploidy in uterus transplant patients |
| title_full_unstemmed | Preimplantation genetic testing for aneuploidy in uterus transplant patients |
| title_short | Preimplantation genetic testing for aneuploidy in uterus transplant patients |
| title_sort | preimplantation genetic testing for aneuploidy in uterus transplant patients |
| url | https://doi.org/10.1177/26334941211009848 |
| work_keys_str_mv | AT rheachattopadhyay preimplantationgenetictestingforaneuploidyinuterustransplantpatients AT elliottrichards preimplantationgenetictestingforaneuploidyinuterustransplantpatients AT valerielibby preimplantationgenetictestingforaneuploidyinuterustransplantpatients AT rebeccaflyckt preimplantationgenetictestingforaneuploidyinuterustransplantpatients |